Gene editing techniques may eventually allow trisomy to be treated at the cellular level, according to an in vitro ...
A temporally resolved CRISPR-Cas9 screen reveals DAC-induced DNA damage drives trans-cell cycle cytotoxicity that depends on ...
This achievement follows Bahrain’s landmark decision on 2 December 2023 to become the second country globally and the first ...
Mammoth Biosciences researchers have developed NanoCas, an ultracompact CRISPR nuclease, demonstrating its ability to perform ...
A new study unravels the relationship between mitofusins (mitochondrial proteins) and autophagy. Using gene editing with CRISPR-Cas9, the team has been able to study these proteins without altering ...
In the spring, five patients with sickle cell disease began treatment with Casgevy, the first FDA-approved CRISPR-Cas9 gene editing treatment. The therapy—which involves removing blood stem ...
Crispr Therapeutics AG has revenue declines but holds strong financials. Promising Sickle Cell therapy & 2025 data readouts ...
Researchers sought to determine whether the CAR-T therapy volamcabtagene durzigedleucel (CTX130) would be effective in patients with T-cell lymphoma.
Ongoing launch of CASGEVY ® continues to gain momentum; new cell patient collection initiations expected to significantly grow in 2025- -More than 50 authorized treatment centers (ATCs) activated ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback